Senti Biosciences (NASDAQ:SNTI) Issues Earnings Results

Senti Biosciences (NASDAQ:SNTI) announced its quarterly earnings results on Friday. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.08), FiscalAI reports. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.01 million.

Senti Biosciences Price Performance

Shares of NASDAQ SNTI traded up $0.07 during midday trading on Friday, hitting $0.45. The company’s stock had a trading volume of 603,575 shares, compared to its average volume of 218,567. The business’s fifty day simple moving average is $0.74 and its two-hundred day simple moving average is $0.87. The firm has a market capitalization of $13.99 million, a price-to-earnings ratio of -0.23 and a beta of 2.10. Senti Biosciences has a 1 year low of $0.33 and a 1 year high of $2.88.

Institutional Trading of Senti Biosciences

Several hedge funds have recently modified their holdings of SNTI. Armistice Capital LLC purchased a new position in Senti Biosciences in the second quarter valued at $1,883,000. Geode Capital Management LLC raised its position in Senti Biosciences by 395.6% in the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after purchasing an additional 117,588 shares in the last quarter. Citadel Advisors LLC purchased a new position in shares of Senti Biosciences in the 3rd quarter valued at about $117,000. Virtu Financial LLC purchased a new position in shares of Senti Biosciences in the 4th quarter valued at about $46,000. Finally, Jane Street Group LLC acquired a new position in shares of Senti Biosciences during the fourth quarter worth about $40,000. 25.70% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently issued reports on SNTI. Weiss Ratings restated a “sell (e+)” rating on shares of Senti Biosciences in a report on Friday, July 17th. Chardan Capital lifted their price target on shares of Senti Biosciences from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, May 15th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $10.00.

Senti Biosciences Company Profile

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.